Gallus BioPharmaceuticals Enters Agreement with Omni Bio Pharmaceutical

Gallus BioPharmaceuticals

, a CMO, and Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of alpha-1 antitrypsin (AAT), reported the finalization of a multi-stage manufacturing services agreement.

The agreement includes cell line optimization, analytical development, and manufacturing scale-up activities for Omni Bio’s AAT Fc fusion protein with the goal of providing cGMP product to support animal toxicology studies and early clinical trials of the molecule. Under the agreement, Omni Bio has selected the commercially available Chozn GS Cell line from Sigma-Aldrich’s custom manufacturing and services business unit SAFC Commercial as the expression system. In addition, SAFC will perform the cell line development and safety testing services, in conjunction with Gallus’ overall management of the process development and manufacturing services program for Omni Bio.

Source:

Gallus BioPharmaceuticals